{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:59:55Z","timestamp":1789541995305,"version":"build-2803163510"},"reference-count":346,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bbadis.2025.167956","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:19:52Z","timestamp":1750216792000},"page":"167956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A review on targeting tunable nanocarrier interaction, physiochemical properties, and futuristic nanocarrier"],"prefix":"10.1016","volume":"1871","author":[{"given":"Sonia","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purnima","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra Singh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2025.167956_bb0005","series-title":"Basic Fundamentals of Drug Delivery","first-page":"269","article-title":"Levels of drug targeting","author":"Yadav","year":"2019"},{"key":"10.1016\/j.bbadis.2025.167956_bb0010","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fphar.2018.00027","article-title":"Transporter-guided delivery of nanoparticles to improve drug permeation across cellular barriers and drug exposure to selective cell types","volume":"9","author":"Kou","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbadis.2025.167956_bb0020","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.2174\/13816128113199990375","article-title":"The smart targeting of nanoparticles","volume":"19","author":"Friedman","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbadis.2025.167956_bb0025","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1557\/mrs2009.119","article-title":"Nanoparticle delivery: targeting and nonspecific binding","volume":"34","author":"Liu","year":"2009","journal-title":"MRS Bull."},{"key":"10.1016\/j.bbadis.2025.167956_bb0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nmat2992","article-title":"The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers","volume":"10","author":"Ashley","year":"2011","journal-title":"Nat. Mater."},{"key":"10.1016\/j.bbadis.2025.167956_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7150\/thno.3463","article-title":"Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy","volume":"2","author":"Yu","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.bbadis.2025.167956_bb0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbadis.2025.167956_bb0045","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.1095833","article-title":"Drug delivery systems: entering the mainstream","volume":"303","author":"Allen","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2025.167956_bb0050","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","article-title":"Active targeting schemes for nanoparticle systems in cancer therapeutics","volume":"60","author":"Byrne","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbadis.2025.167956_bb0055","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1073\/pnas.95.8.4607","article-title":"Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment","volume":"95","author":"Hobbs","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2025.167956_bb0060","first-page":"209","article-title":"New developments in angiogenesis: a major mechanism for tumour growth and target for therapy","volume":"4","author":"Jones","year":"1998","journal-title":"Cancer J. Sci. Am."},{"key":"10.1016\/j.bbadis.2025.167956_bb0065","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF00409698","article-title":"Vascularization of tumors: a review","volume":"103","author":"Shubik","year":"1982","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0070","first-page":"3752","article-title":"Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size","volume":"55","author":"Yuan","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2025.167956_bb0075","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/jpm11060571","article-title":"Recent advances in tumor targeting via EPR effect for cancer treatment","volume":"11","author":"Subhan","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.bbadis.2025.167956_bb0080","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0085","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/03639045.2021.1934869","article-title":"A review of stimuli-responsive polymeric micelles for tumor-targeted delivery of curcumin","volume":"47","author":"Qiu","year":"2021","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.bbadis.2025.167956_bb0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1039\/D4CC05098C","article-title":"Smart polymers: key to targeted therapeutic interventions","volume":"61","author":"Thakkar","year":"2025","journal-title":"Chem. Commun."},{"key":"10.1016\/j.bbadis.2025.167956_bb0095","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1073\/pnas.1522080113","article-title":"Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy","volume":"113","author":"Li","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2025.167956_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/VIW.20200042","article-title":"Smart materials for drug delivery and cancer therapy","volume":"2","author":"Yang","year":"2021","journal-title":"View"},{"key":"10.1016\/j.bbadis.2025.167956_bb0105","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2008.09.074","article-title":"Drug targeting and tumor heterogeneity","volume":"133","author":"Bae","year":"2008","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2025.167956_bb0110","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrc3180","article-title":"Treating metastatic cancer with nanotechnology","volume":"12","author":"Schroeder","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbadis.2025.167956_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1201\/9780429399039-2","article-title":"Nanocarriers as an emerging platform for cancer therapy","author":"Peer","year":"2020","journal-title":"Nano-enabled Med. Appl."},{"key":"10.1016\/j.bbadis.2025.167956_bb0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/09687688.2010.510804","article-title":"Nanoparticulate drug delivery systems for cancer chemotherapy","volume":"27","author":"Saha","year":"2010","journal-title":"Mol. Membr. Biol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fmolb.2020.00193","article-title":"Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance","volume":"7","author":"Yao","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.bbadis.2025.167956_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2022.100080","article-title":"Recent developments in nanocarriers for cancer chemotherapy","volume":"8","author":"Dastidar","year":"2022","journal-title":"OpenNano"},{"key":"10.1016\/j.bbadis.2025.167956_bb0135","article-title":"Advances in targeted therapy for tumor with nanocarriers: a review","volume":"31","author":"Cheng","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.bbadis.2025.167956_bb0140","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","article-title":"Challenges in development of nanoparticle-based therapeutics","volume":"14","author":"Desai","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.bbadis.2025.167956_bb0145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbadis.2025.167956_bb0150","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5194780","article-title":"Physical properties of nanoparticles that result in improved cancer targeting","volume":"2020","author":"Zein","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0155","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejpb.2011.08.004","article-title":"Expert opinion: responsive polymer nanoparticles in cancer therapy","volume":"80","author":"Liechty","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.bbadis.2025.167956_bb0160","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1021\/acs.bioconjchem.6b00437","article-title":"Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?","volume":"27","author":"Nakamura","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bbadis.2025.167956_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2040-2384-2-14","article-title":"Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability","volume":"2","author":"Sarin","year":"2010","journal-title":"J. Angiogenes. Res."},{"key":"10.1016\/j.bbadis.2025.167956_bb0170","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11095-008-9697-x","article-title":"Intravascular delivery of particulate systems: does geometry really matter?","volume":"26","author":"Decuzzi","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bbadis.2025.167956_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-7-51","article-title":"Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors","volume":"7","author":"Sarin","year":"2009","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbadis.2025.167956_bb0180","doi-asserted-by":"crossref","first-page":"F605","DOI":"10.1152\/ajprenal.00171.2004","article-title":"Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: effects of molecular size, shape, charge, and deformability","volume":"288","author":"Venturoli","year":"2005","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0185","doi-asserted-by":"crossref","first-page":"19048","DOI":"10.1073\/pnas.1315336110","article-title":"Photoswitchable nanoparticles for in vivo cancer chemotherapy","volume":"110","author":"Tong","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2025.167956_bb0190","doi-asserted-by":"crossref","first-page":"8848","DOI":"10.1021\/ja211888a","article-title":"Photoswitchable nanoparticles for triggered tissue penetration and drug delivery","volume":"134","author":"Tong","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bbadis.2025.167956_bb0195","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1073\/pnas.1018382108","article-title":"Multistage nanoparticle delivery system for deep penetration into tumor tissue","volume":"108","author":"Wong","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2025.167956_bb0200","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.addr.2020.06.005","article-title":"Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers","volume":"157","author":"Fang","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbadis.2025.167956_bb0205","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1021\/acsnano.9b08142","article-title":"Meta-analysis of nanoparticle delivery to tumors using a physiologically based pharmacokinetic modeling and simulation approach","volume":"14","author":"Cheng","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbadis.2025.167956_bb0210","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nrc.2017.93","article-title":"Transport of drugs from blood vessels to tumour tissue","volume":"17","author":"Dewhirst","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbadis.2025.167956_bb0215","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jconrel.2017.04.024","article-title":"Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses","volume":"256","author":"Kang","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2025.167956_bb0220","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1021\/nn500299p","article-title":"Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency","volume":"8","author":"Sykes","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbadis.2025.167956_bb0225","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jconrel.2022.12.028","article-title":"Applications and challenges of ultra-small particle size nanoparticles in tumor therapy","volume":"353","author":"Xu","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2025.167956_bb0230","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1021\/acscentsci.9b01139","article-title":"Size-tunable strategies for a tumor targeted drug delivery system","volume":"6","author":"Yu","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb0235","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/jat.2758","article-title":"Time-dependent biodistribution and excretion of silver nanoparticles in male Wistar rats","volume":"32","author":"Dziendzikowska","year":"2012","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0240","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1073\/pnas.1216893110","article-title":"Particle shape enhances specificity of antibody-displaying nanoparticles","volume":"110","author":"Barua","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2025.167956_bb0245","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1021\/nl204175t","article-title":"Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation","volume":"12","author":"Smith","year":"2012","journal-title":"Nano Lett."},{"key":"10.1016\/j.bbadis.2025.167956_bb0250","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1021\/nn300149c","article-title":"Synthesis and biological response of size-specific, monodisperse drug\u2013silica nanoconjugates","volume":"6","author":"Tang","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbadis.2025.167956_bb0255","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2217\/nnm.13.191","article-title":"Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles","volume":"9","author":"Toy","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.bbadis.2025.167956_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202007880","article-title":"Can the shape of nanoparticles enable the targeting to cancer cells over healthy cells?","volume":"31","author":"Cong","year":"2021","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.bbadis.2025.167956_bb0265","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jbiomech.2008.03.021","article-title":"The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows","volume":"41","author":"Gentile","year":"2008","journal-title":"J. Biomech."},{"key":"10.1016\/j.bbadis.2025.167956_bb0270","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/adfm.201503664","article-title":"A bio-inspired rod-shaped nanoplatform for strongly infecting tumor cells and enhancing the delivery efficiency of anticancer drugs","volume":"26","author":"Li","year":"2016","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.bbadis.2025.167956_bb0275","article-title":"Linear chimeric triblock molecules self-assembled micelles with controllably transformable property to enhance tumor retention for chemo-photodynamic therapy of breast cancer","volume":"29","author":"Liu","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.bbadis.2025.167956_bb0280","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nnano.2007.70","article-title":"Shape effects of filaments versus spherical particles in flow and drug delivery","volume":"2","author":"Geng","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0285","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jconrel.2010.07.116","article-title":"Polymer particle shape independently influences binding and internalization by macrophages","volume":"147","author":"Sharma","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2025.167956_bb0290","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1021\/nn300652p","article-title":"Enhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radio-frequency-tunable drug release","volume":"6","author":"Peiris","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbadis.2025.167956_bb0295","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nnano.2010.203","article-title":"Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T 1 contrast","volume":"5","author":"Ananta","year":"2010","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0300","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1021\/acsnano.5b00147","article-title":"Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting","volume":"9","author":"Anselmo","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbadis.2025.167956_bb0305","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz4316","article-title":"Nanoparticle elasticity regulates phagocytosis and cancer cell uptake","volume":"6","author":"Hui","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbadis.2025.167956_bb0310","doi-asserted-by":"crossref","first-page":"E1142","DOI":"10.1073\/pnas.1521265113","article-title":"Tailoring nanoparticle designs to target cancer based on tumor pathophysiology","volume":"113","author":"Sykes","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2025.167956_bb0315","doi-asserted-by":"crossref","first-page":"9912","DOI":"10.1021\/acsnano.5b05792","article-title":"Microfluidic synthesis of hybrid nanoparticles with controlled lipid layers: understanding flexibility-regulated cell\u2013nanoparticle interaction","volume":"9","author":"Zhang","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbadis.2025.167956_bb0320","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41467-017-02588-9","article-title":"Nanoparticle elasticity directs tumor uptake","volume":"9","author":"Guo","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2025.167956_bb0325","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1038\/s41467-022-31882-4","article-title":"Nanoparticle elasticity affects systemic circulation lifetime by modulating adsorption of apolipoprotein AI in corona formation","volume":"13","author":"Li","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2025.167956_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121879","article-title":"Elasticity regulates nanomaterial transport as delivery vehicles: design, characterization, mechanisms and state of the art","volume":"291","author":"Nie","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbadis.2025.167956_bb0335","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.0801763105","article-title":"The effect of particle design on cellular internalization pathways","volume":"105","author":"Gratton","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2025.167956_bb0340","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbrc.2006.11.135","article-title":"Targeting of nanoparticles to the clathrin-mediated endocytic pathway","volume":"353","author":"Harush-Frenkel","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbadis.2025.167956_bb0345","doi-asserted-by":"crossref","first-page":"302","DOI":"10.7150\/thno.13686","article-title":"Active tumor permeation and uptake of surface charge-switchable theranostic nanoparticles for imaging-guided photothermal\/chemo combinatorial therapy","volume":"6","author":"Hung","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.bbadis.2025.167956_bb0350","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.apsb.2021.03.033","article-title":"Influencing factors and strategies of enhancing nanoparticles into tumors in vivo","volume":"11","author":"Zhang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbadis.2025.167956_bb0355","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-5173(02)00129-1","article-title":"Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating","volume":"240","author":"Levchenko","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbadis.2025.167956_bb0360","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/mp800049w","article-title":"Pharmacokinetics and biodistribution of nanoparticles","volume":"5","author":"Li","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbadis.2025.167956_bb0365","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0973-0168.197974","article-title":"Understanding the basic role of glycocalyx during cancer","volume":"7","author":"Lahir","year":"2016","journal-title":"J. Radiat. Cancer Res."},{"key":"10.1016\/j.bbadis.2025.167956_bb0370","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1002\/adma.201404715","article-title":"Peptide assembly integration of fibroblast-targeting and cell-penetration features for enhanced antitumor drug delivery","volume":"27","author":"Ji","year":"2015","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bbadis.2025.167956_bb0375","doi-asserted-by":"crossref","first-page":"16227","DOI":"10.1021\/acsami.6b03254","article-title":"Hydrogen sulfide triggered charge-reversal micelles for cancer-targeted drug delivery and imaging","volume":"8","author":"Zhang","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bbadis.2025.167956_bb0380","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.bpj.2010.06.016","article-title":"Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions","volume":"99","author":"Stylianopoulos","year":"2010","journal-title":"Biophys. J."},{"key":"10.1016\/j.bbadis.2025.167956_bb0385","first-page":"135","article-title":"Targeted drug delivery system: a review","volume":"1","author":"Manish","year":"2011","journal-title":"Res. J. Chem. Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb0390","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12551-012-0072-0","article-title":"Toward a molecular understanding of nanoparticle\u2013protein interactions","volume":"4","author":"Treuel","year":"2012","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.bbadis.2025.167956_bb0395","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/nano10020240","article-title":"Protein corona composition of silica nanoparticles in complex media: nanoparticle size does not matter","volume":"10","author":"Marichal","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.bbadis.2025.167956_bb0400","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/mp800051m","article-title":"Factors affecting the clearance and biodistribution of polymeric nanoparticles","volume":"5","author":"Alexis","year":"2008","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbadis.2025.167956_bb0405","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1039\/D2LC00799A","article-title":"Nanoparticle protein corona: from structure and function to therapeutic targeting","volume":"23","author":"Bashiri","year":"2023","journal-title":"Lab Chip"},{"key":"10.1016\/j.bbadis.2025.167956_bb0410","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1021\/nn500962q","article-title":"Nanoparticles for imaging, sensing, and therapeutic intervention","volume":"8","author":"Bogart","year":"2014","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbadis.2025.167956_bb0415","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1073\/pnas.0608582104","article-title":"Understanding the nanoparticle\u2013protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles","volume":"104","author":"Cedervall","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2025.167956_bb0420","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.nantod.2016.10.005","article-title":"Emerging understanding of the protein corona at the nano-bio interfaces","volume":"11","author":"Mahmoudi","year":"2016","journal-title":"Nano Today"},{"key":"10.1016\/j.bbadis.2025.167956_bb0425","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2025.167956_bb0430","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.tibtech.2016.08.011","article-title":"Biological identity of nanoparticles in vivo: clinical implications of the protein corona","volume":"35","author":"Caracciolo","year":"2017","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0435","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.biomaterials.2010.05.027","article-title":"The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation","volume":"31","author":"Kedmi","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbadis.2025.167956_bb0440","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1039\/C4BM00131A","article-title":"Personalized protein coronas: a \u201ckey\u201d factor at the nanobiointerface","volume":"2","author":"Hajipour","year":"2014","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb0445","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2016.07.009","article-title":"Liver sinusoidal endothelial cells: physiology and role in liver diseases","volume":"66","author":"Poisson","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0450","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nnano.2012.237","article-title":"Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface","volume":"8","author":"Salvati","year":"2013","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0455","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jconrel.2012.04.009","article-title":"Designing the nanoparticle\u2013biomolecule interface for \u201ctargeting and therapeutic delivery\u201d","volume":"161","author":"Mahon","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2025.167956_bb0460","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/pharmaceutics11010031","article-title":"Protein corona fingerprints of liposomes: new opportunities for targeted drug delivery and early detection in pancreatic cancer","volume":"11","author":"Palchetti","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbadis.2025.167956_bb0470","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2217\/nnm.15.6","article-title":"Exploiting the novel properties of protein coronas: emerging applications in nanomedicine","volume":"10","author":"Hamad-Schifferli","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.bbadis.2025.167956_bb0475","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbadis.2025.167956_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024696","article-title":"A systems approach for tumor pharmacokinetics","volume":"6","author":"Thurber","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2025.167956_bb0485","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41565-018-0171-6","article-title":"Pre-adsorption of antibodies enables targeting of nanocarriers despite a biomolecular corona","volume":"13","author":"Tonigold","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0490","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/ph17050612","article-title":"Blood\u2013brain barrier-targeting nanoparticles: biomaterial properties and biomedical applications in translational neuroscience","volume":"17","author":"Asimakidou","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbadis.2025.167956_bb0495","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.3390\/ijms23084153","article-title":"Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology","volume":"23","author":"Hersh","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb0500","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12951-024-02511-7","article-title":"Brain-targeted drug delivery-nanovesicles directed to specific brain cells by brain-targeting ligands","volume":"22","author":"Moreira","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0505","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.actbio.2015.05.010","article-title":"Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells","volume":"23","author":"Zhao","year":"2015","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bbadis.2025.167956_bb0510","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bbadis.2025.167956_bb0520","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1083\/jcb.201102147","article-title":"The extracellular matrix: a dynamic niche in cancer progression","volume":"196","author":"Lu","year":"2012","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbplus.2021.100060","article-title":"The role of the multifaceted long non-coding RNAs: a nuclear-cytosolic interplay to regulate hyaluronan metabolism","volume":"11","author":"Parnigoni","year":"2021","journal-title":"Matrix Biol. Plus"},{"key":"10.1016\/j.bbadis.2025.167956_bb0530","first-page":"2497","article-title":"Role of extracellular matrix assembly in interstitial transport in solid tumors","volume":"60","author":"Netti","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbadis.2025.167956_bb0535","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.593197","article-title":"Overcoming biological barriers with block copolymers-based self-assembled nanocarriers. Recent advances in delivery of anticancer therapeutics","volume":"11","author":"Torres","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0540","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.addr.2007.06.008","article-title":"Endocytic mechanisms for targeted drug delivery","volume":"59","author":"Bareford","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbadis.2025.167956_bb0545","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nantod.2014.04.008","article-title":"Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects","volume":"9","author":"Barua","year":"2014","journal-title":"Nano Today"},{"key":"10.1016\/j.bbadis.2025.167956_bb0550","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/biomimetics8020146","article-title":"The extracellular matrix: its composition, function, remodeling, and role in tumorigenesis","volume":"8","author":"Dzobo","year":"2023","journal-title":"Biomimetics"},{"key":"10.1016\/j.bbadis.2025.167956_bb0555","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.3390\/cancers13184523","article-title":"Detection of lysyl oxidase activity in tumor extracellular matrix using peptide-functionalized gold nanoprobes","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbadis.2025.167956_bb0560","doi-asserted-by":"crossref","first-page":"14845","DOI":"10.1021\/acsami.6b04737","article-title":"pH-activated targeting drug delivery system based on the selective binding of phenylboronic acid","volume":"8","author":"Zhao","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bbadis.2025.167956_bb0565","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1039\/C8TB02600A","article-title":"Multifunctional sharp pH-responsive nanoparticles for targeted drug delivery and effective breast cancer therapy","volume":"7","author":"Yao","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.bbadis.2025.167956_bb0570","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3390\/cells10030541","article-title":"Targeting the hypoxic and acidic tumor microenvironment with ph-sensitive peptides","volume":"10","author":"Dharmaratne","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bbadis.2025.167956_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103414","article-title":"pH and its applications in targeted drug delivery","volume":"28","author":"Abdella","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbadis.2025.167956_bb0580","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/s41598-017-01956-1","article-title":"Single-cell pH imaging and detection for pH profiling and label-free rapid identification of cancer-cells","volume":"7","author":"Hou","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2025.167956_bb0585","series-title":"Nanostructures for Drug Delivery","first-page":"1","article-title":"Therapeutic nanomaterials: from a drug delivery perspective","author":"Kumar","year":"2017"},{"key":"10.1016\/j.bbadis.2025.167956_bb0590","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1039\/D1TB02349G","article-title":"The influence of surface charge on the tumor-targeting behavior of Fe3O4 nanoparticles for MRI","volume":"10","author":"Yue","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.bbadis.2025.167956_bb0595","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5301\/JBM.2011.6372","article-title":"Decreased expression of decorin and p57 (KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients","volume":"26","author":"Biaoxue","year":"2011","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.bbadis.2025.167956_bb0600","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-\u03b2-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2025.167956_bb0605","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1124\/pr.109.001289","article-title":"Extracellular matrix molecules: potential targets in pharmacotherapy","volume":"61","author":"J\u00e4rvel\u00e4inen","year":"2009","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bbadis.2025.167956_bb0610","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/jso.20745","article-title":"Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors","volume":"96","author":"Matsumine","year":"2007","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0615","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/07357900701788148","article-title":"The extracellular matrix protein 1: its molecular interaction and implication in tumor progression","volume":"26","author":"Sercu","year":"2008","journal-title":"Cancer Investig."},{"key":"10.1016\/j.bbadis.2025.167956_bb0620","first-page":"207","article-title":"Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer","volume":"9","author":"Troup","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2025.167956_bb0625","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3390\/pharmaceutics10030162","article-title":"Doxorubicin-conjugated PAMAM dendrimers for pH-responsive drug release and folic acid-targeted cancer therapy","volume":"10","author":"Zhang","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbadis.2025.167956_bb0630","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbadis.2025.167956_bb0635","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jconrel.2015.08.017","article-title":"Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors","volume":"219","author":"Miao","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2025.167956_bb0640","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jconrel.2020.12.005","article-title":"Biomimetic nanoarchitecturing: a disguised attack on cancer cells","volume":"329","author":"Jha","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2025.167956_bb0645","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1021\/acsnano.6b02776","article-title":"The binding site barrier elicited by tumor-associated fibroblasts interferes disposition of nanoparticles in stroma-vessel type tumors","volume":"10","author":"Miao","year":"2016","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbadis.2025.167956_bb0650","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1038\/sj.onc.1209597","article-title":"Glycolysis inhibition for anticancer treatment","volume":"25","author":"Pelicano","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2025.167956_bb0655","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2174\/1389450117666160602202339","article-title":"Recent advances in pH-sensitive polymeric nanoparticles for smart drug delivery in cancer therapy","volume":"19","author":"Lim","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bbadis.2025.167956_bb0660","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbadis.2025.167956_bb0665","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2025.167956_bb0670","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn900002m","article-title":"Impact of nanotechnology on drug delivery","volume":"3","author":"Farokhzad","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbadis.2025.167956_bb0675","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.phrs.2016.08.024","article-title":"Enzyme-responsive multistage vector for drug delivery to tumor tissue","volume":"113","author":"Mi","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbadis.2025.167956_bb0680","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1021\/nn200876f","article-title":"Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia","volume":"5","author":"Poon","year":"2011","journal-title":"ACS Nano"},{"key":"10.1016\/j.bbadis.2025.167956_bb0685","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3109\/1061186X.2016.1172587","article-title":"Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticles","volume":"24","author":"Ramishetti","year":"2016","journal-title":"J. Drug Target."},{"key":"10.1016\/j.bbadis.2025.167956_bb0690","series-title":"Semin Cancer Biol","first-page":"166","article-title":"Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy","volume":"vol. 69","author":"Raj","year":"2021"},{"key":"10.1016\/j.bbadis.2025.167956_bb0695","first-page":"916","article-title":"Transferrin receptor 1 in cancer: a new sight for cancer therapy","volume":"8","author":"Shen","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbadis.2025.167956_bb0700","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.clim.2006.06.010","article-title":"The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer","volume":"121","author":"Daniels","year":"2006","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0705","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1021\/acs.bioconjchem.6b00611","article-title":"Rational design of a transferrin-binding peptide sequence tailored to targeted nanoparticle internalization","volume":"28","author":"Santi","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bbadis.2025.167956_bb0710","first-page":"1","article-title":"Transferrin receptor targeting chimeras for membrane protein degradation","author":"Zhang","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2025.167956_bb0715","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1073\/pnas.92.9.3824","article-title":"Folate receptors targeted to clathrin-coated pits cannot regulate vitamin uptake","volume":"92","author":"Ritter","year":"1995","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb0720","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1083\/jcb.110.3.637","article-title":"The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway","volume":"110","author":"Rothberg","year":"1990","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0725","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/srep00980","article-title":"Nuclear localization of folate receptor alpha: a new role as a transcription factor","volume":"2","author":"Boshnjaku","year":"2012","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2025.167956_bb0730","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0378-1119(00)00418-2","article-title":"Identification of two putative novel folate receptor genes in humans and mouse","volume":"258","author":"Spiegelstein","year":"2000","journal-title":"Gene"},{"key":"10.1016\/j.bbadis.2025.167956_bb0735","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nature12327","article-title":"Structural basis for molecular recognition of folic acid by folate receptors","volume":"500","author":"Chen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2025.167956_bb0740","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.9651","article-title":"Targeting folate receptor alpha for cancer treatment","volume":"7","author":"Cheung","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbadis.2025.167956_bb0745","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cbpa.2009.03.022","article-title":"Folate-targeted therapeutic and imaging agents for cancer","volume":"13","author":"Low","year":"2009","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0750","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.ygyno.2024.11.008","article-title":"Following the folate receptor: expanding targeted treatment options in low grade serous ovarian carcinoma","volume":"191","author":"Thayer","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0755","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41568-020-00322-0","article-title":"Antitumour immunity regulated by aberrant ERBB family signalling","volume":"21","author":"Kumagai","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbadis.2025.167956_bb0760","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cells6020013","article-title":"Activation of the EGF receptor by ligand binding and oncogenic mutations: the \u201crotation model\u201d","volume":"6","author":"Purba","year":"2017","journal-title":"Cells"},{"key":"10.1016\/j.bbadis.2025.167956_bb0765","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/med.20070","article-title":"Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development","volume":"26","author":"Kamath","year":"2006","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bbadis.2025.167956_bb0770","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3892\/ol.2015.3277","article-title":"Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma","volume":"10","author":"Lin","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bbadis.2025.167956_bb0775","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-9-6","article-title":"Evaluation of gene amplification and protein expression of HER-2\/neu in esophageal squamous cell carcinoma using fluorescence in situ hybridization (FISH) and immunohistochemistry","volume":"9","author":"Sato-Kuwabara","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbadis.2025.167956_bb0780","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1172\/JCI36049","article-title":"Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family","volume":"118","author":"Shepard","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2025.167956_bb0785","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00432-004-0610-7","article-title":"Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma","volume":"131","author":"Sunpaweravong","year":"2005","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0790","article-title":"EGFR targeting for cancer therapy: pharmacology and immunoconjugates with drugs and nanoparticles","volume":"592","author":"da Silva Santos","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbadis.2025.167956_bb0795","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejmech.2017.07.023","article-title":"How to train your inhibitor: design strategies to overcome resistance to epidermal growth factor receptor inhibitors","volume":"142","author":"Milik","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbadis.2025.167956_bb0800","article-title":"Central nervous system as a sanctuary for advanced epidermal growth factor receptor-mutant non-small cell lung cancer","volume":"21","author":"Gabriel Lenz","year":"2025","journal-title":"touchREVIEWS Oncol. Haematol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0605-5","article-title":"The biology and role of CD44 in cancer progression: therapeutic implications","volume":"11","author":"Chen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0810","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbadis.2025.167956_bb0815","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-020-00192-0","article-title":"CD44 as a tumor biomarker and therapeutic target","volume":"9","author":"Xu","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0820","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00418-019-01835-y","article-title":"Evaluating nuclear translocation of surface receptors: recommendations arising from analysis of CD44","volume":"153","author":"Thorne","year":"2020","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0825","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/JCMA.0000000000000056","article-title":"The subpopulation of CD44-positive cells promoted tumorigenicity and metastatic ability in lung adenocarcinoma","volume":"82","author":"Wang","year":"2019","journal-title":"J. Chin. Med. Assoc."},{"key":"10.1016\/j.bbadis.2025.167956_bb0830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4569-1","article-title":"Elevated expression of hyaluronan synthase 2 associates with decreased survival in diffusely infiltrating astrocytomas","volume":"18","author":"Valkonen","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbadis.2025.167956_bb0835","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.3390\/biomedicines10102488","article-title":"CD44 promotes breast cancer metastasis through AKT-mediated downregulation of nuclear FOXA2","volume":"10","author":"Vadhan","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbadis.2025.167956_bb0840","first-page":"1","article-title":"CD44+ cells enhance pro-tumor stroma in the spatial landscape of colorectal cancer leading edge","author":"Tang","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2025.167956_bb0845","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbadis.2025.167956_bb0850","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41390-020-01177-9","article-title":"The role of integrins in inflammation and angiogenesis","volume":"89","author":"Mezu-Ndubuisi","year":"2021","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bbadis.2025.167956_bb0855","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13045-021-01192-1","article-title":"Integrins regulate stemness in solid tumor: an emerging therapeutic target","volume":"14","author":"Xiong","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0860","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","article-title":"Every step of the way: integrins in cancer progression and metastasis","volume":"18","author":"Hamidi","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbadis.2025.167956_bb0865","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.tips.2021.07.001","article-title":"Peptide\u2013drug conjugate-based novel molecular drug delivery system in cancer","volume":"42","author":"Zhu","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb0870","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.bbadis.2025.167956_bb0875","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/jnci\/dji130","article-title":"Specific occlusion of murine and human tumor vasculature by VCAM-1\u2013targeted recombinant fusion proteins","volume":"97","author":"Dienst","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbadis.2025.167956_bb0880","doi-asserted-by":"crossref","first-page":"9739","DOI":"10.3390\/ijms21249739","article-title":"The roles of matrix metalloproteinases and their inhibitors in human diseases","volume":"21","author":"Cabral-Pacheco","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb0885","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"key":"10.1016\/j.bbadis.2025.167956_bb0890","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood-2023-174193","article-title":"Interim phase I safety study of anti-transferrin receptor antibody (PPMX-T003) in patients with polycythemia vera","volume":"142","author":"Ito","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2025.167956_bb0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104167","article-title":"11P preclinical evaluation of an anti-transferrin receptor antibody drug conjugate targeting triple-negative breast cancer","volume":"10","author":"Launay","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.bbadis.2025.167956_bb0900","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A phase 2\/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbadis.2025.167956_bb0905","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial","volume":"36","author":"Secord","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0910","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70274","article-title":"Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody\u2013drug conjugates, show activity in poor prognosis gynaecological cancer models","volume":"15","author":"Nesic","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bbadis.2025.167956_bb0920","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2024.07.675","article-title":"Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: a randomized, multicenter clinical trial","volume":"189","author":"Gupta","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0925","author":"Zeneca"},{"key":"10.1016\/j.bbadis.2025.167956_bb0930","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2025.167956_bb0935","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1038\/s41467-025-58435-9","article-title":"Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial","volume":"16","author":"Bian","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbadis.2025.167956_bb0940","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae336","article-title":"Aumolertinib plus chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 19 deletion or exon 21 L858R: a phase II trial","volume":"30","author":"Li","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.bbadis.2025.167956_bb0945","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/14796694.2025.2457294","article-title":"REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC","volume":"21","author":"Heymach","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0950","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO-24-01269","article-title":"First-line mobocertinib versus platinum-based chemotherapy in patients with EGFR exon 20 insertion\u2013positive metastatic non\u2013small cell lung cancer in the phase III EXCLAIM-2 trial","volume":"43","author":"J\u00e4nne","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0955","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3892\/or.2024.8806","article-title":"Antitumor activities of anti-CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer","volume":"52","author":"Ishikawa","year":"2024","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbadis.2025.167956_bb0960","unstructured":"Y. Bei, J. He, X. Dong, Y. Wang, W. Guo, C. Cai, Z. Xu, J. Wei, B. Liu, P. Shen, Targeting CD44 Variant 5 by an Antibody\u2013Drug Conjugate as a Novel Therapeutic Regimen for Intrahepatic Cholangiocarcinoma, Available at SSRN 4290063."},{"key":"10.1016\/j.bbadis.2025.167956_bb0965","article-title":"The development and potent antitumor efficacy of CD44\/CD133 dual-targeting IL7R\u03b1-armored CAR-T cells against glioblastoma","volume":"217541","author":"Zhai","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbadis.2025.167956_bb0970","article-title":"A phase Ib\/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics\/pharmacodynamics of \u03b1v\u03b23\/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma","volume":"41","author":"Xu","year":"2023","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0975","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","article-title":"Targeting integrin pathways: mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbadis.2025.167956_bb0985","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2025.167956_bb0990","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1146\/annurev.cellbio.17.1.463","article-title":"How matrix metalloproteinases regulate cell behavior","volume":"17","author":"Sternlicht","year":"2001","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.bbadis.2025.167956_bb0995","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.192","article-title":"Targeting inorganic nanoparticles to tumors using biological membrane-coated technology","volume":"3","author":"Zhang","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.bbadis.2025.167956_bb1000","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3390\/molecules22091445","article-title":"Unique roles of gold nanoparticles in drug delivery, targeting and imaging applications","volume":"22","author":"Kong","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.bbadis.2025.167956_bb1005","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s12274-014-0697-3","article-title":"How toxic are gold nanoparticles? The state-of-the-art","volume":"8","author":"Fratoddi","year":"2015","journal-title":"Nano Res."},{"key":"10.1016\/j.bbadis.2025.167956_bb1010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.msec.2016.04.030","article-title":"In vitro cytotoxicity and phototoxicity of surface-modified gold nanoparticles associated with neutral red as a potential drug delivery system in phototherapy","volume":"65","author":"Verissimo","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.bbadis.2025.167956_bb1015","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1021\/acsomega.9b04150","article-title":"Gold nanoshell-linear tetrapyrrole conjugates for near infrared-activated dual photodynamic and photothermal therapies","volume":"5","author":"Wang","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.bbadis.2025.167956_bb1020","article-title":"Gold nanoparticle based photothermal therapy: development and application for effective cancer treatment","volume":"22","author":"Yang","year":"2019","journal-title":"Sustain. Mater. Technol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1025","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.biotechadv.2012.10.002","article-title":"Gold nanoparticles: emerging paradigm for targeted drug delivery system","volume":"31","author":"Kumar","year":"2013","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.bbadis.2025.167956_bb1030","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e42738","article-title":"Utilizing gold nanoparticles in plasmonic photothermal therapy for cancer treatment","volume":"11","author":"Badir","year":"2025","journal-title":"Heliyon"},{"key":"10.1016\/j.bbadis.2025.167956_bb1035","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3390\/cancers13081825","article-title":"Recent development of gold nanoparticles as contrast agents for cancer diagnosis","volume":"13","author":"Luo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbadis.2025.167956_bb1040","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2024.1484577","article-title":"Utilization of nanomaterials in MRI contrast agents and their role in therapy guided by imaging","volume":"12","author":"Wang","year":"2024","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1045","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1182\/blood-2023-185400","article-title":"Photoablation with the aurolase system reduces T cell exhaustion and synergizes with immunotherapies in lymphoma","volume":"142","author":"Lin","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2025.167956_bb1050","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2174\/1389557516666160321113620","article-title":"Mesoporous silica nanoparticles in cancer therapy: relevance of the targeting function","volume":"16","author":"Pasqua","year":"2016","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.bbadis.2025.167956_bb1055","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/2230-973X.160844","article-title":"Mesoporous silica nanoparticles in target drug delivery system: a review","volume":"5","author":"Bharti","year":"2015","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.bbadis.2025.167956_bb1060","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1021\/acs.langmuir.5b00139","article-title":"Gated mesoporous silica nanoparticles for the controlled delivery of drugs in cancer cells","volume":"31","author":"Gimenez","year":"2015","journal-title":"Langmuir"},{"key":"10.1016\/j.bbadis.2025.167956_bb1065","doi-asserted-by":"crossref","DOI":"10.1177\/2041731413503357","article-title":"Silica-based mesoporous nanoparticles for controlled drug delivery","volume":"4","author":"Kwon","year":"2013","journal-title":"J. Tissue Eng."},{"key":"10.1016\/j.bbadis.2025.167956_bb1070","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.molcatb.2006.02.002","article-title":"Highly efficient immobilization of endo-1, 3-\u03b2-d-glucanases (laminarinases) from marine mollusks in novel hybrid polysaccharide-silica nanocomposites with regulated composition","volume":"40","author":"Shchipunov","year":"2006","journal-title":"J. Mol. Catal. B Enzym."},{"key":"10.1016\/j.bbadis.2025.167956_bb1075","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41392-023-01654-7","article-title":"Multifunctional mesoporous silica nanoparticles for biomedical applications","volume":"8","author":"Xu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbadis.2025.167956_bb1080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12645-024-00250-w","article-title":"Mesoporous silica nanotechnology: promising advances in augmenting cancer theranostics","volume":"15","author":"Dutta Gupta","year":"2024","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1085","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202400323","article-title":"Mesoporous silica nanoparticles as an ideal platform for cancer immunotherapy: recent advances and future directions","volume":"13","author":"Godakhindi","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.bbadis.2025.167956_bb1090","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2021.644564","article-title":"Drug delivery with carbon-based nanomaterials as versatile nanocarriers: progress and prospects","volume":"3","author":"Debnath","year":"2021","journal-title":"Front. Nanotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1095","first-page":"2963","article-title":"A new era of cancer treatment: carbon nanotubes as drug delivery tools","author":"Madani","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbadis.2025.167956_bb1100","doi-asserted-by":"crossref","DOI":"10.3389\/fbiom.2025.1500758","article-title":"The cutting-edge applications and properties of carbon nanotubes in diagnosis and treatment of lung cancer: a review","volume":"4","author":"Abdollahi Boraei","year":"2025","journal-title":"Front. Biomater. Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb1105","series-title":"Quantum dots and their applications: what lies ahead?","first-page":"4920","volume":"vol. 3","author":"Cotta","year":"2020"},{"key":"10.1016\/j.bbadis.2025.167956_bb1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2020.116013","article-title":"Role of quantum dots in pharmaceutical and biomedical analysis, and its application in drug delivery","volume":"131","author":"Bad\u0131ll\u0131","year":"2020","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/j.bbadis.2025.167956_bb1115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.actbio.2019.05.022","article-title":"Quantum dots in biomedical applications","volume":"94","author":"Wagner","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bbadis.2025.167956_bb1120","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/acsmaterialslett.0c00550","article-title":"Graphene quantum dots (GQDs) for bioimaging and drug delivery applications: a review","volume":"3","author":"Biswas","year":"2021","journal-title":"ACS Mater. Lett."},{"key":"10.1016\/j.bbadis.2025.167956_bb1125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241612682","article-title":"Current advances in the biomedical applications of quantum dots: promises and challenges","volume":"24","author":"Le","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb1130","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.2147\/IJN.S138624","article-title":"Quantum dots in imaging, drug delivery and sensor applications","author":"Matea","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbadis.2025.167956_bb1135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1140","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12951-023-02235-0","article-title":"Recent trends in preparation and biomedical applications of iron oxide nanoparticles","volume":"22","author":"Meng","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1145","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.36922\/td.1356","article-title":"Targeted drug delivery approaches for the management of tumors","volume":"2","author":"Misra","year":"2023","journal-title":"Tumor Discov."},{"key":"10.1016\/j.bbadis.2025.167956_bb1150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.actbio.2019.11.027","article-title":"Targeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy","volume":"102","author":"Zhi","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bbadis.2025.167956_bb1155","article-title":"Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment","volume":"2","author":"Ghazal","year":"2024","journal-title":"Next Mater."},{"key":"10.1016\/j.bbadis.2025.167956_bb1160","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1039\/c3nr02797j","article-title":"Gadolinium embedded iron oxide nanoclusters as T 1\u2013T 2 dual-modal MRI-visible vectors for safe and efficient siRNA delivery","volume":"5","author":"Wang","year":"2013","journal-title":"Nanoscale"},{"key":"10.1016\/j.bbadis.2025.167956_bb1165","article-title":"Ultrasmall Fe3O4 nanoparticles self-assembly induced dual-mode T1\/T2-weighted magnetic resonance imaging and enhanced tumor synergetic theranostics","volume":"14","author":"Xie","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2025.167956_bb1170","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.2147\/IJN.S87148","article-title":"Nanotechnology-based drug delivery systems for the treatment of Alzheimer\u2019s disease","author":"Fonseca-Santos","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbadis.2025.167956_bb1175","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1180","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201705328","article-title":"Advances in biomaterials for drug delivery","volume":"30","author":"Fenton","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bbadis.2025.167956_bb1185","series-title":"Lipid Nanocarriers, Lipid Nanocarriers for Drug Targeting","first-page":"1","author":"Shukla","year":"2018"},{"key":"10.1016\/j.bbadis.2025.167956_bb1190","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3390\/nano9040638","article-title":"Lipid-based nanoparticles: application and recent advances in cancer treatment","volume":"9","author":"Garc\u00eda-Pinel","year":"2019","journal-title":"Nanomaterials"},{"key":"10.1016\/j.bbadis.2025.167956_bb1195","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.actbio.2015.09.032","article-title":"Engineering the lipid layer of lipid\u2013PLGA hybrid nanoparticles for enhanced in vitro cellular uptake and improved stability","volume":"28","author":"Hu","year":"2015","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bbadis.2025.167956_bb1200","doi-asserted-by":"crossref","first-page":"24013","DOI":"10.1021\/acsami.3c00307","article-title":"Tumor microenvironment-inspired glutathione-responsive three-dimensional fibrous network for efficient trapping and gentle release of circulating tumor cells","volume":"15","author":"Luo","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bbadis.2025.167956_bb1205","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1515\/ejnm-2016-0009","article-title":"Solid lipid nanoparticles encapsulating a fluorescent marker (coumarin 6) and antimalarials\u2013artemether and lumefantrine: evaluation of cellular uptake and antimalarial activity","volume":"8","author":"Attama","year":"2016","journal-title":"Eur. J. Nanomed."},{"key":"10.1016\/j.bbadis.2025.167956_bb1210","first-page":"17","article-title":"A recent update: solid lipid nanoparticles for effective drug delivery","volume":"12","author":"Pandey","year":"2021","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.bbadis.2025.167956_bb1215","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.colsurfb.2007.03.002","article-title":"Studies on oral absorption of stearic acid SLN by a novel fluorometric method","volume":"58","author":"Yuan","year":"2007","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.bbadis.2025.167956_bb1220","first-page":"337","article-title":"Moisturizing effects of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) using deionized and magnetized water by in vivo and in vitro methods","volume":"23","author":"Sarhadi","year":"2020","journal-title":"Iran. J. Basic Med. Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb1225","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43094-022-00414-8","article-title":"Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours","volume":"8","author":"Garg","year":"2022","journal-title":"Futur. J. Pharm. Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb1230","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biopha.2018.04.055","article-title":"Nanostructured lipid carriers for site-specific drug delivery","volume":"103","author":"Khosa","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbadis.2025.167956_bb1235","doi-asserted-by":"crossref","first-page":"8685","DOI":"10.1021\/acs.langmuir.8b01211","article-title":"Toward understanding liposome-based siRNA delivery vectors: atomic-scale insight into siRNA\u2013lipid interactions","volume":"34","author":"Antipina","year":"2018","journal-title":"Langmuir"},{"key":"10.1016\/j.bbadis.2025.167956_bb1240","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/17425247.2019.1669558","article-title":"Lipid-based nanoparticle formulations for small molecules and RNA drugs","volume":"16","author":"Ickenstein","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.bbadis.2025.167956_bb1245","article-title":"Niosomes: a review on niosomal research in the last decade","volume":"56","author":"Bhardwaj","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1250","article-title":"Niosome: a promising nanocarrier for natural drug delivery through blood-brain barrier","volume":"2018","author":"Gharbavi","year":"2018","journal-title":"Adv. Pharmacol. Pharm. Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb1255","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-642-00477-3_2","article-title":"Nanoparticle technologies for cancer therapy","author":"Alexis","year":"2010","journal-title":"Drug Deliv."},{"key":"10.1016\/j.bbadis.2025.167956_bb1260","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1166\/jnn.2015.10298","article-title":"Applications of nanoparticles for anticancer drug delivery: a review","volume":"15","author":"Zhu","year":"2015","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1265","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.2147\/IJN.S146315","article-title":"Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors","author":"Din","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbadis.2025.167956_bb1270","doi-asserted-by":"crossref","first-page":"8230","DOI":"10.1158\/1078-0432.CCR-05-1895","article-title":"Liposomal, nanoparticle, and conjugated formulations of anticancer agents","volume":"11","author":"Zamboni","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2025.167956_bb1275","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1159131","article-title":"Dendrimer: an update on recent developments and future opportunities for the brain tumors diagnosis and treatment","volume":"14","author":"Kaurav","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1280","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1021\/mp3005325","article-title":"Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry","volume":"10","author":"Lo","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbadis.2025.167956_bb1285","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/1521-3773(20020415)41:8<1329::AID-ANIE1329>3.0.CO;2-P","article-title":"Dendritic polymers in biomedical applications: from potential to clinical use in diagnostics and therapy","volume":"41","author":"Stiriba","year":"2002","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bbadis.2025.167956_bb1290","article-title":"PAMAM dendrimers based co-delivery of methotrexate and berberine for targeting of Hela cancer cells","volume":"13","author":"Majidzadeh","year":"2024","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.bbadis.2025.167956_bb1295","doi-asserted-by":"crossref","DOI":"10.1038\/srep23179","article-title":"Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer","volume":"6","author":"Kulhari","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2025.167956_bb1300","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejps.2015.12.031","article-title":"Recent advances in polymeric micelles for anti-cancer drug delivery","volume":"83","author":"Biswas","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb1305","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nnano.2011.166","article-title":"Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size","volume":"6","author":"Cabral","year":"2011","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1310","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1049\/nbt2.12018","article-title":"Nanomicelles: types, properties and applications in drug delivery","volume":"15","author":"Bose","year":"2021","journal-title":"IET Nanobiotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1315","first-page":"5230","article-title":"Micelles as delivery system for cancer treatment","volume":"23","author":"Keskin","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbadis.2025.167956_bb1320","doi-asserted-by":"crossref","DOI":"10.1515\/ntrev-2023-0218","article-title":"Micelle-based nanoparticles with stimuli-responsive properties for drug delivery","volume":"13","author":"Maboudi","year":"2024","journal-title":"Nanotechnol. Rev."},{"key":"10.1016\/j.bbadis.2025.167956_bb1325","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yexmp.2008.12.004","article-title":"Nanoparticle-based targeted drug delivery","volume":"86","author":"Singh","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1330","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.2147\/IJN.S158696","article-title":"Stimuli-responsive polymeric micelles for drug delivery and cancer therapy","author":"Zhou","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbadis.2025.167956_bb1335","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1039\/D3PM00053B","article-title":"Indocyanine green within glycosylated polymeric micelles as potential image agents to map sentinel lymph nodes and breast cancer","volume":"1","author":"Lecot","year":"2024","journal-title":"RSC Pharmaceutics"},{"key":"10.1016\/j.bbadis.2025.167956_bb1340","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/sj.bjc.6602479","article-title":"NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel","volume":"92","author":"Hamaguchi","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2025.167956_bb1345","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/bjc.2011.6","article-title":"A phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours","volume":"104","author":"Plummer","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbadis.2025.167956_bb1350","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/molecules27041372","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bbadis.2025.167956_bb1355","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.601626","article-title":"Biodegradable polymeric nanoparticles for drug delivery to solid tumors","volume":"12","author":"Gagliardi","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1360","series-title":"Nanomaterials for Drug Delivery and Therapy","first-page":"59","article-title":"Theranostics application of nanomedicine in cancer detection and treatment","author":"Siddhardha","year":"2019"},{"key":"10.1016\/j.bbadis.2025.167956_bb1365","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8844030","article-title":"Dendrimers: a new race of pharmaceutical nanocarriers","volume":"2021","author":"Mittal","year":"2021","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bbadis.2025.167956_bb1370","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1039\/C1NR11188D","article-title":"Gold nanoparticles: preparation, properties, and applications in bionanotechnology","volume":"4","author":"Yeh","year":"2012","journal-title":"Nanoscale"},{"key":"10.1016\/j.bbadis.2025.167956_bb1375","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2025.117180","article-title":"Quantum dots for biosensing: classification and applications","volume":"273","author":"Quesada-Gonz\u00e1lez","year":"2025","journal-title":"Biosens. Bioelectron."},{"key":"10.1016\/j.bbadis.2025.167956_bb1380","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2174\/1389450124666230817103122","article-title":"Bio-functional mesoporous silica nanoparticles as nano-structured carriers in cancer theranostic review on recent advancements","volume":"24","author":"Gevariya","year":"2023","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bbadis.2025.167956_bb1385","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/jjco\/hyn116","article-title":"Polymeric micellar delivery systems in oncology","volume":"38","author":"Matsumura","year":"2008","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1390","article-title":"Magnetic nanosystem a tool for targeted delivery and diagnostic application: current challenges and recent advancement","volume":"7","author":"Rarokar","year":"2024","journal-title":"Int. J. Pharm.: X"},{"key":"10.1016\/j.bbadis.2025.167956_bb1395","article-title":"Rise of antibody-drug conjugates: the present and future","volume":"43","author":"Shastry","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.bbadis.2025.167956_bb1400","series-title":"Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type","author":"Beasley","year":"2025"},{"key":"10.1016\/j.bbadis.2025.167956_bb1405","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41417-023-00701-3","article-title":"The target atlas for antibody-drug conjugates across solid cancers","volume":"31","author":"Fang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bbadis.2025.167956_bb1410","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bbadis.2025.167956_bb1415","author":"U.S.F.D.A"},{"key":"10.1016\/j.bbadis.2025.167956_bb1420","first-page":"OF1","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbadis.2025.167956_bb1425","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1430","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1200\/JCO.2018.36.4_suppl.711","article-title":"Influence of liposomal irinotecan (nal-IRI) and non-liposomal irinotecan, alone and in combination, on tumor growth and angiogenesis in colorectal cancer (CRC) models","volume":"36","author":"Larsen","year":"2018","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1435","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jconrel.2020.07.007","article-title":"Delivering the power of nanomedicine to patients today","volume":"326","author":"Germain","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2025.167956_bb1440","author":"National Cancer Institute Nanodelivery Systems and Devices"},{"key":"10.1016\/j.bbadis.2025.167956_bb1445","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1450","author":"U.S.F.D.A"},{"key":"10.1016\/j.bbadis.2025.167956_bb1455","author":"U.S.F.D.A"},{"key":"10.1016\/j.bbadis.2025.167956_bb1460","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40291-022-00594-2","article-title":"Lutetium Lu 177 vipivotide tetraxetan: first approval","volume":"26","author":"Keam","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.bbadis.2025.167956_bb1465","author":"U.S.F.D.A"},{"key":"10.1016\/j.bbadis.2025.167956_bb1470","author":"U.S.F.D.A"},{"key":"10.1016\/j.bbadis.2025.167956_bb1475","author":"U.S.F.D.A"},{"key":"10.1016\/j.bbadis.2025.167956_bb1480","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab vedotin: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bbadis.2025.167956_bb1485","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","article-title":"Moxetumomab pasudotox: first global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bbadis.2025.167956_bb1490","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s40265-017-0802-5","article-title":"Inotuzumab ozogamicin: first global approval","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bbadis.2025.167956_bb1495","author":"U.S.F.D.A"},{"key":"10.1016\/j.bbadis.2025.167956_bb1500","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1182\/bloodadvances.2019000173","article-title":"Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm","volume":"4","author":"Pemmaraju","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.bbadis.2025.167956_bb1505","author":"U.S.F.D.A"},{"key":"10.1016\/j.bbadis.2025.167956_bb1510","author":"U.S.F.D.A"},{"key":"10.1016\/j.bbadis.2025.167956_bb1515","author":"U.S.F.D.A"},{"key":"10.1016\/j.bbadis.2025.167956_bb1520","author":"U.S.F.D.A"},{"key":"10.1016\/j.bbadis.2025.167956_bb1525","author":"U.S.F.D.A"},{"key":"10.1016\/j.bbadis.2025.167956_bb1530","author":"U.S.F.D.A"},{"key":"10.1016\/j.bbadis.2025.167956_bb1535","article-title":"Gold nanoparticles in transferrin-targeted dual-drug delivery in vitro","volume":"90","author":"David","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1540","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1021\/mp100207t","article-title":"Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancer","volume":"7","author":"Chattopadhyay","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbadis.2025.167956_bb1545","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1021\/nl802915q","article-title":"Engineering of hetero-functional gold nanorods for the in vivo molecular targeting of breast cancer cells","volume":"9","author":"Eghtedari","year":"2009","journal-title":"Nano Lett."},{"key":"10.1016\/j.bbadis.2025.167956_bb1550","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10549-010-0811-5","article-title":"Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells","volume":"125","author":"Carpin","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbadis.2025.167956_bb1555","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.canlet.2008.09.024","article-title":"In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles","volume":"274","author":"Li","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbadis.2025.167956_bb1560","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3390\/antiox12081617","article-title":"Kinetic effects of transferrin-conjugated gold nanoparticles on the antioxidant glutathione-thioredoxin pathway","volume":"12","author":"Sebastian","year":"2023","journal-title":"Antioxidants"},{"key":"10.1016\/j.bbadis.2025.167956_bb1565","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2018.04.005","article-title":"Theranostic size-reducible and no donor conjugated gold nanocluster fabricated hyaluronic acid nanoparticle with optimal size for combinational treatment of breast cancer and lung metastasis","volume":"278","author":"Liu","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2025.167956_bb1570","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.actbio.2021.04.006","article-title":"Dual-responsive nanohybrid based on degradable silica-coated gold nanorods for triple-combination therapy for breast cancer","volume":"128","author":"Cheng","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bbadis.2025.167956_bb1575","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijpharm.2017.04.060","article-title":"SN38 conjugated hyaluronic acid gold nanoparticles as a novel system against metastatic colon cancer cells","volume":"526","author":"Hosseinzadeh","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbadis.2025.167956_bb1580","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.apsb.2018.05.011","article-title":"Gold nanorods together with HSP inhibitor-VER-155008 micelles for colon cancer mild-temperature photothermal therapy","volume":"8","author":"Tang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbadis.2025.167956_bb1585","first-page":"6773","article-title":"Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy","author":"Amreddy","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbadis.2025.167956_bb1590","article-title":"Evaluation of cytotoxic activity of docetaxel loaded gold nanoparticles for lung cancer drug delivery","volume":"21","author":"Thambiraj","year":"2019","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.bbadis.2025.167956_bb1595","article-title":"Epidermal growth factor receptors siRNA-conjugated collagen modified gold nanoparticles for targeted imaging and therapy of lung cancer","volume":"12","author":"Yu","year":"2021","journal-title":"Mater. Today Adv."},{"key":"10.1016\/j.bbadis.2025.167956_bb1600","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1039\/b816209c","article-title":"Cyclodextrin-covered gold nanoparticles for targeted delivery of an anti-cancer drug","volume":"19","author":"Park","year":"2009","journal-title":"J. Mater. Chem."},{"key":"10.1016\/j.bbadis.2025.167956_bb1605","doi-asserted-by":"crossref","first-page":"18462","DOI":"10.1021\/acsami.7b02457","article-title":"pH-sensitive delivery vehicle based on folic acid-conjugated polydopamine-modified mesoporous silica nanoparticles for targeted cancer therapy","volume":"9","author":"Cheng","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.bbadis.2025.167956_bb1610","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1021\/acsanm.9b01921","article-title":"Transferrin-conjugated polymer-coated mesoporous silica nanoparticles loaded with gemcitabine for killing pancreatic cancer cells","volume":"3","author":"Saini","year":"2019","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.bbadis.2025.167956_bb1615","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2021.118822","article-title":"Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy","volume":"277","author":"Lohiya","year":"2022","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.bbadis.2025.167956_bb1620","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1021\/acsabm.9b00036","article-title":"Redox stimuli delivery vehicle based on transferrin-capped MSNPs for targeted drug delivery in cancer therapy","volume":"2","author":"Venkatesan","year":"2019","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.bbadis.2025.167956_bb1625","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.msec.2016.05.013","article-title":"Effects of transferrin conjugated multi-walled carbon nanotubes in lung cancer delivery","volume":"67","author":"Singh","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.bbadis.2025.167956_bb1630","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/cas.12865","article-title":"Role of hemoglobin and transferrin in multi-wall carbon nanotube-induced mesothelial injury and carcinogenesis","volume":"107","author":"Wang","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbadis.2025.167956_bb1635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.125386","article-title":"Study of folate-based carbon nanotube drug delivery systems targeted to folate receptor \u03b1 by molecular dynamic simulations","volume":"244","author":"Jiang","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1640","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/bab.1592","article-title":"Size of single-wall carbon nanotube affects the folate receptor-mediated cancer cell targeting","volume":"65","author":"Charbgoo","year":"2018","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.bbadis.2025.167956_bb1645","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1039\/c2tb00434h","article-title":"Non-covalent conjugates of single-walled carbon nanotubes and folic acid for interaction with cells over-expressing folate receptors","volume":"1","author":"Castillo","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.bbadis.2025.167956_bb1650","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbagen.2015.09.021","article-title":"CdTe quantum dots as fluorescent probes to study transferrin receptors in glioblastoma cells","volume":"1860","author":"Cabral Filho","year":"2016","journal-title":"Biochim. Biophys. Acta, Gen. Subj."},{"key":"10.1016\/j.bbadis.2025.167956_bb1655","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.aca.2012.06.043","article-title":"Characterization of CdTe\/CdSe quantum dots-transferrin fluorescent probes for cellular labeling","volume":"741","author":"Guan","year":"2012","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.bbadis.2025.167956_bb1660","doi-asserted-by":"crossref","first-page":"15453","DOI":"10.1039\/C7NR05838A","article-title":"A novel type of quantum dot\u2013transferrin conjugate using DNA hybridization mimics intracellular recycling of endogenous transferrin","volume":"9","author":"Banerjee","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.bbadis.2025.167956_bb1665","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1007\/s11696-023-02733-3","article-title":"Interactions of CdSe and CdSe@ ZnS quantum dots with transferrin and effects on the iron ions release","volume":"77","author":"Zhou","year":"2023","journal-title":"Chem. Pap."},{"key":"10.1016\/j.bbadis.2025.167956_bb1670","doi-asserted-by":"crossref","DOI":"10.1002\/anie.201202876","article-title":"Conjugation of transferrin to azide-modified CdSe\/ZnS Core\u2013Shell Quantum Dots using Cyclooctyne Click Chemistry","volume":"51","author":"Schieber","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.bbadis.2025.167956_bb1675","doi-asserted-by":"crossref","DOI":"10.1016\/j.jphotobiol.2020.111918","article-title":"Evaluating internalization and recycling of folate receptors in breast cancer cells using quantum dots","volume":"209","author":"Monteiro","year":"2020","journal-title":"J. Photochem. Photobiol. B Biol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1680","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-49171-5","article-title":"Enhanced anti-tumor activity of transferrin\/folate dual-targeting magnetic nanoparticles using chemo-thermo therapy on retinoblastoma cancer cells Y79","volume":"13","author":"Sadri","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2025.167956_bb1685","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2021.102467","article-title":"Transferrin receptors\/magnetic resonance dual-targeted nanoplatform for precise chemo-photodynamic synergistic cancer therapy","volume":"39","author":"Ge","year":"2022","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.bbadis.2025.167956_bb1690","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.2147\/IJN.S215087","article-title":"CD44-targeted magnetic nanoparticles kill head and neck squamous cell carcinoma stem cells in an alternating magnetic field","author":"Su","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbadis.2025.167956_bb1695","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jbiotec.2021.03.010","article-title":"Transferrin-functionalized lipid nanoparticles for curcumin brain delivery","volume":"331","author":"Neves","year":"2021","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1700","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113525","article-title":"Folate receptor-mediated delivery of mitoxantrone-loaded solid lipid nanoparticles to breast cancer cells","volume":"154","author":"Granja","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbadis.2025.167956_bb1705","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.canlet.2012.07.002","article-title":"Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer","volume":"334","author":"Yang","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbadis.2025.167956_bb1710","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121034","article-title":"Transferrin-conjugated liposomes loaded with carnosic acid inhibit liver cancer growth by inducing mitochondria-mediated apoptosis","volume":"607","author":"Liu","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbadis.2025.167956_bb1715","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109323","article-title":"Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model","volume":"118","author":"de Oliveira Silva","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbadis.2025.167956_bb1720","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1016\/j.biomaterials.2012.03.067","article-title":"CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma","volume":"33","author":"Wang","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.bbadis.2025.167956_bb1725","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.colsurfb.2017.07.064","article-title":"Surface modification of docetaxel nanocrystals with HER2 antibody to enhance cell growth inhibition in breast cancer cells","volume":"159","author":"Choi","year":"2017","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.bbadis.2025.167956_bb1730","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejpb.2017.01.020","article-title":"A new targeted delivery approach by functionalizing drug nanocrystals through polydopamine coating","volume":"114","author":"Zhan","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.bbadis.2025.167956_bb1735","first-page":"502","article-title":"Methotrexate delivery via folate targeted dendrimer-based nanotherapeutic platform","volume":"1","author":"Majoros","year":"2009","journal-title":"Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.bbadis.2025.167956_bb1740","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1007\/s11095-013-1295-x","article-title":"Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: efficient killing of paclitaxel-resistant cancer cells","volume":"31","author":"Abouzeid","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bbadis.2025.167956_bb1745","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jconrel.2021.01.022","article-title":"Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo","volume":"331","author":"Andrade","year":"2021","journal-title":"J. Control. Release"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443925003047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443925003047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:50:23Z","timestamp":1788295823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443925003047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":346,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0925443925003047"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2025.167956","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review on targeting tunable nanocarrier interaction, physiochemical properties, and futuristic nanocarrier","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2025.167956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"167956"}}